Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: lamamakara	3/2/2006 10:46:16 AM
	of 3044

The panel also agreed that the approval of Revlimid and increased marketing focus from both Celgene and Millennium will prove to reduce the use of VAD and melphalan/prednisone in multiple myeloma. In their view, while Revlimid/ melphalan/prednisone could become the standard of care for elderly patients, the use of VAD is likely to decrease. They also believe that Celgene report + IMS ---------------------------- the role of bone marrow transplantation will decline due the availability of Thalomid, Velcade and Revlimid. Finally, the consensus among the panelists was that Velcade could have some role in front-line multiple myeloma, although in a limited capacity in high risk patients with chromosomal translocations. filelodge.com filelodge.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next